Merus (NASDAQ:MRUS) Earns “Buy” Rating from Guggenheim

Merus (NASDAQ:MRUS)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a note issued to investors on Wednesday,Benzinga reports.

Other research analysts have also recently issued research reports about the company. Needham & Company LLC reissued a “buy” rating and issued a $85.00 price objective on shares of Merus in a research note on Monday, December 9th. The Goldman Sachs Group assumed coverage on Merus in a research note on Thursday, November 21st. They issued a “buy” rating and a $73.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $85.00 price objective on shares of Merus in a research note on Monday, December 2nd. Citigroup increased their price objective on Merus from $89.00 to $97.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Finally, UBS Group assumed coverage on Merus in a research note on Thursday, October 24th. They issued a “buy” rating and a $72.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Merus presently has an average rating of “Buy” and an average price target of $86.08.

Merus Price Performance

Shares of MRUS traded down $0.10 during mid-day trading on Wednesday, reaching $40.02. 10,849 shares of the company’s stock traded hands, compared to its average volume of 582,022. Merus has a 12 month low of $37.77 and a 12 month high of $61.61. The stock has a market cap of $2.74 billion, a P/E ratio of -10.13 and a beta of 1.11. The stock’s 50-day moving average is $41.94 and its two-hundred day moving average is $47.52.

Institutional Trading of Merus

Hedge funds and other institutional investors have recently made changes to their positions in the business. nVerses Capital LLC lifted its holdings in shares of Merus by 750.0% during the 3rd quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 1,500 shares during the last quarter. Avior Wealth Management LLC purchased a new stake in shares of Merus during the 4th quarter valued at $76,000. US Bancorp DE purchased a new stake in shares of Merus during the 3rd quarter valued at $103,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Merus by 24.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 489 shares during the last quarter. Finally, MML Investors Services LLC purchased a new stake in shares of Merus during the 3rd quarter valued at $206,000. Hedge funds and other institutional investors own 96.14% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.